Showing results (101-110 of 180) with videos related to

Sort By:
Pageof 18
Journal for Immunotherapy of Cancer|March 20, 2021
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow nicheLouise M E Müller, Gemma Migneco, Gina B Scott, et al.
Eclinicalmedicine|August 9, 2023
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialJohn R Jones, David A Cairns, Tom Menzies, et al.
Blood|October 28, 2020
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsAbi Vijenthira, Inna Y Gong, Thomas A Fox, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Haematologica|December 3, 2009
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemiaCharles Craddock, Sandeep Nagra, Andrew Peniket, et al.
British Journal of Haematology|November 19, 2015
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocolsRachael Hough, Robert Danby, Nigel Russell, et al.
Future Oncology (London, England)|March 1, 2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myelomaCaitlin Costello, Faith E Davies, Gordon Cook, et al.
Blood|January 12, 2012
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)Oliver C Goodyear, Mike Dennis, Nadira Y Jilani, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Pageof 18